LGC to Launch Global Beer and Tonic Products with CLV Frontier Brands Joint Venture

Symbol: TSX-V: LG

MONTREAL, April 18, 2018 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce that CLV Frontier Brands Pty Ltd ("CLV"), its equal one-third joint venture with UK-based Baltic Beer Company Ltd and ASX-listed Creso Pharma Limited, is planning to have its first beers and tonics on sale in Europe and Canada during the summer, with global sales to follow shortly thereafter.  CLV is developing a bespoke and unique range of beers and tonics at its newly-built facilities in Europe, with test brewing well advanced.  LGC is also pleased to announce that the TSX Venture Exchange has conditionally accepted LGC's joint venture investment in CLV, subject to LGC filing standard documentation with the Exchange.

John McMullen, CEO of LGC stated, "We view CLV partnership as an exciting business opportunity and as our commitment to providing high quality medical cannabis products globally over the coming years.  Full details of the beer and tonic ranges will be released when CLV debuts its products and branding at a world-wide product launch.  Europe will be the initial focus for sales, due to Europe being the home market for the Baltic Beer Company's multi award winning Viru beer, but we are pushing to also launch in Canada this summer."

CLV's beer contains terpenes, which carry the flavour and aroma of cannabis and do not contain THC or CBD or any other cannabinoids.  The terpenes used in CLV's beer will not contain cannabis or hemp ingredients, as may have been referred to in previous LGC press releases.  The terpenes are extracted from various plant sources, all of which are food-grade, 100% natural and non-genetically modified (GMO) ingredients.  The terpenes are pure, not contaminated with any other ingredient, and safe for human consumption as flavouring ingredients, meeting the criteria of FDA/FEMA GRAS (generally recognized as safe) for human consumption.  The terpenes are introduced to the beer at the post-fermentation stage in much the same manner as hop extracts are added.

About LGC (www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG).  LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services with an emphasis on significant investments in global medical cannabis sector.

About Baltic Beer Company Ltd (www.virubeer.com)

A UK based company that created and markets an iconic Estonian beer brand called Viru Premium Estonian Beer.  Viru beer is currently sold in numerous markets around the world including Australia, China, UK, Italy and Mexico to name a few and has won multiple awards including gold medals at Monde Selection, Brussels and the World Beer Championships Chicago.

About Creso Pharma (www.cresopharma.com)

Creso Pharma brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.  It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.  Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.  It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

FORWARD-LOOKING STATEMENTS 
This press release may contain forward-looking statements with respect to LGC Capital Ltd. ("LGC") and CLV Frontier Brands Pty Ltd ("CLV"), and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward- looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of LGC and CLV could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under "Risk Factors and Risk Management" in LGC's Management's Discussion and Analysis for the fiscal year ended September 30, 2017, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor CLV has any obligation to update such statements, except to the extent required by applicable securities laws.

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE LGC Capital Ltd

John McMullen, Chief Executive Officer, Tel.: [phone], Email: [email protected]; London contact: Anthony Samaha, Chief Financial Officer, Tel.: [phone], Investor Relations: Dave Burwell, The Howard Group Inc., Tel.: [phone], Toll Free: 1-888-221-0915, Email: [email protected]